Smiths buys US drug delivery firm for pounds 100m
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SMITHS Industries, the aerospace, industrial and medical equipment group, is paying dollars 150m ( pounds 100m) to acquire Deltec, a US maker of intravenous drug delivery systems, from Pharmacia, the Swedish drug company that is in the process of being privatised, writes Terence Wilkinson.
Deltec makes infusion systems in which electronic pumps are used, together with disposable cassettes, to administer long-term intravenous medication to patients who would otherwise be confined to hospital beds. Typical users are diabetics and Aids sufferers.
The company also makes the Port-a-Cath range of implantable vascular access ports and catheters, which allow drugs to be administered over a long period without repeated needle punctures.
Pressure on budgets means there is a growing trend towards providing health care away from hospital locations wherever possible. An increasing number of drugs are provided intravenously and demographic changes mean there will be more older people needing continuing care.
Smiths sees the purchase as a strategic step in building a community healthcare device system. Net assets being acquired are dollars 51m and the core US business made profits of dollars 13.3m on sales of dollars 90m.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments